The investigators will perform single-dose pharmacokinetic (PK) studies in humans following administration of drugs with known microbiome derived metabolism (MDM) in parallel with preclinical studies. By directly comparing laboratory measurements to clinical results, the investigators will be able to confirm the relevance of MDM in vivo, create microbiome-dependent PK profiles of the MDM positive drugs, and establish methodology to capture the contribution of MDM to inter-individual variability in clinical drug PK profiles.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Drug area under the plasma concentration versus time curve (AUC)
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)
Drug peak plasma concentration
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)
Drug trough plasma concentrations
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)
Drug volume of distribution
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)
Drug half-life
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)
Drug plasma clearance
Timeframe: After a single dose of a microbiome derived metabolism positive drug (over an 8 hour period for each drug)